The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.
|Podcasts|March 25, 2021
Podcast: OCT is a dynamic test
Author(s)Benjamin P. Casella, OD, FAAO
Advertisement
Chief Optometric Editor Ben Casella, OD, FAAO, illustrates how optical coherence tomography (OCT) is a dynamic test. A Friday afternoon patient exhibited a macular smudge, and Dr. Casella performed OCT to investigate further.
Advertisement
Related to this article
As artificial intelligence advances, so do VR devices.
Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.
Bita Asghari, OD, FAAO, FSLS, discusses diagnosing ocular surface inflammation, recognizing atypical keratitis, and knowing when to refer to a cornea specialist.
The approval followed complete response letters tied to inspection and manufacturing issues.
What to take away on PBM, hormonal eye health, and GLP-1 receptor agonists from this year’s meeting.
From treating myopic complications to preventing them, eye care providers have ample opportunity to close a collaborative care gap.
The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 pm ET and was open to public.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Takeaways from this week in optometry: November 9-13
2
Yuvezzi now available through telehealth for adults with presbyopia
3
Scope Health launches Optase Heat Mask Pro for MGD and dry eye
4
Jarett Mazzarella, OD, on his career as a VA optometrist
5